Histology—N (%) | |
Ductal | 199 (57.7) |
Lobular | 56 (16.2) |
Mixed | 56 (16.2) |
Othera | 34 (9.9) |
Average tumor size (mm) | |
Mean (SD) | 15.66 (7.90) |
Min–max | 1.00–50.00 |
Tumor size, distribution—N (%) | |
T < 20 mm | 261 (75.7) |
20 mm < T ≤ 50 mm | 84 (24.3) |
Site of tumor—N (%) | |
QII | 21 (6.1) |
QSI | 46 (13.3) |
QSE | 225 (65.2) |
QIE | 45 (13.0) |
CENTRAL | 8 (2.3) |
Ki-67—(% expression) | |
Mean (SD) | 15.02 (10.18) |
Min–max | 5.00–80.00 |
Distribution of Ki-67 expression levels—N (%) | |
Low (0–13 % of cells) | 198 (57.4) |
Intermediate (14–9 % of cells) | 60 (17.4) |
High (≥20 % of cells) | 87 (25.2) |
Patients with ER positivity—N (%) | 297 (86.1) |
ER positivity per patient—(% expression) | |
Mean (DS) | 65.23 (33.35) |
Min–max | 0.00–100.00 |
Patients with PGR positivity—N (%) | 275 (79.7) |
PgR ≥20 % expression | 238 (69.0) |
PgR positivity per patient—(% expression) | |
Mean (SD) | 50.83 (36.59) |
Min–max | 0.00–100.00 |
Patients with HER2 positivity—N (%) | 45 (13.0) |
Distribution of histological grades—N (%) | |
Grade 1 | 69 (20.0) |
Grade 2 | 175 (50.7) |
Grade 3 | 101 (29.3) |
Tumor subtypes—N (%) | |
Patients with luminal subtype | 297 (86.1) |
luminal A | 225 (75.8) |
luminal B | 72 (24.2) |
Patients with HER 2 subtype | 21 (6.1) |
Patients with triple negative subtype | 27 (7.8) |
Patients with LVI—N (%) | 109 (31.6) |
Patients with extensive DCIS/LCIS | 98 (28.4) |